MP29-02 clinical trials
Also written MP29-02.
How each study uses MP29-02 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MP29-02
- 3
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Studies
Open first, then newest update. How each study uses MP29-02 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone PropionateWithdrawnNot applicableUniversity Hospital, GhentNCT02883439Written as MP29-02How we know
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesCompletedPhase 3Meda PharmaceuticalsNCT00651118Written as azelastineHcl / fluticasone propionateHow we know
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal AllergiesCompletedPhase 3Meda PharmaceuticalsNCT00660517Written as MP29-02How we know